Combined proteasome and histone deacetylase inhibition in non–small cell lung cancer
- 30 April 2004
- journal article
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 127 (4) , 1078-1086
- https://doi.org/10.1016/s0022-5223(03)01321-7
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxinProceedings of the National Academy of Sciences, 2002
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2002
- Lung Cancer — Time to Move on from ChemotherapyNew England Journal of Medicine, 2002
- Histone deacetylase inhibitors in cancer treatmentAnti-Cancer Drugs, 2002
- Histone deacetylase inhibitors as new cancer drugsCurrent Opinion in Oncology, 2001
- Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group TrialJournal of Clinical Oncology, 2001
- Histone deacetylase inhibitor selectively induces p21 WAF1 expression and gene-associated histone acetylationProceedings of the National Academy of Sciences, 2000
- Histone Deacetylase Inhibition Selectively Alters the Activity and Expression of Cell Cycle Proteins Leading to Specific Chromatin Acetylation and Antiproliferative EffectsJournal of Biological Chemistry, 1999
- Role of the histone deacetylase complex in acute promyelocytic leukaemiaNature, 1998
- Role of histone deacetylases in acute leukemiaJournal of Cellular Biochemistry, 1998